Jie Huang

Dr. Jie Huang


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2024 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
SWShun Wang
Shun Wang
RWRuohuang Wang
Ruohuang Wang
DHDingtao Hu
Dingtao Hu
CZCaoxu Zhang
Caoxu Zhang
PCPeng Cao
Peng Cao
JHJie Huang
Jie Huang
Cancer cell growth, metastasis, and drug resistance pose significant challenges in the management of lung adenocarcinoma (LUAD). However, there is a deficiency in optimal predictive models capable of accurately forecasting patient prognoses and guiding the selection of targeted treatments. Programmed cell death (PCD) pathways play a pivotal role in the development and progression of various cancers, offering potential as prognostic indicators and drug sensitivity markers for LUAD patients. The development and validation of predictive models were conducted by integrating 13 PCD patterns with comprehensive analysis of bulk RNA, single-cell RNA transcriptomics, and pertinent clinicopathological details derived from TCGA-LUAD and six GEO datasets. Utilizing the machine learning algorithms, we identified ten critical differentially expressed genes associated with PCD in LUAD, namely CHEK2, KRT18, RRM2, GAPDH, MMP1, CHRNA5, TMPRSS4, ITGB4, CD79A, and CTLA4. Subsequently, we conducted a programmed cell death index (PCDI) based on these genes across the aforementioned cohorts and integrated this index with relevant clinical features to develop several prognostic nomograms. Furthermore, we observed a significant correlation between the PCDI and immune features in LUAD, including immune cell infiltration and the expression of immune checkpoint molecules. Additionally, we found that patients with a high PCDI score may exhibit resistance to immunotherapy and standard adjuvant chemotherapy regimens; however, they may benefit from other FDA-supported drugs such as docetaxel and dasatinib. In conclusion, the PCDI holds potential as a prognostic signature and can facilitate personalized treatment for LUAD patients.

18 July 2025 in npj Precision Oncology
Verified
Journal Article
Open access
SWShun Wang
Shun Wang
DHDingtao Hu
Dingtao Hu
RWRuohuang Wang
Ruohuang Wang
JHJie Huang
Jie Huang
BWBaoqing Wang
Baoqing Wang
Lung adenocarcinoma (LUAD) is a major cause of cancer-related mortality globally. Proliferating cells, crucial components of the tumor immune microenvironment (TIME), play a significant role in cancer progression and immunotherapy response. Herein, we utilized multi-omics data and employed a multifaceted approach to delineate the proliferating cell landscape in LUAD. The Scissor algorithm was applied to identify Scissor+ proliferating cell genes associated with prognosis. An integrative machine learning program, comprising 111 algorithms, was developed to construct a Scissor+ proliferating cell risk score (SPRS). The SPRS model demonstrated superior performance in predicting prognosis and clinical outcomes compared to 30 previously published models. The role of SPRS and five pivotal genes in immunotherapy response was evaluated, and their expression was experimentally verified. Multifactorial analysis confirmed SPRS as an independent prognostic factor affecting LUAD patient survival. High- and low-SPRS groups exhibited different biological functions and immune cell infiltration in the TIME. High SPRS patients showed resistance to immunotherapy but increased sensitivity to chemotherapeutic and targeted therapeutic agents. Our study elucidates the dynamics of proliferating cells in LUAD, enhancing prognostic accuracy and highlighting the potential of SPRS and its constituent genes for personalized therapeutic interventions.

5 June 2024 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
SWShun Wang
Shun Wang
RWRuohuang Wang
Ruohuang Wang
DHDingtao Hu
Dingtao Hu
CZCaoxu Zhang
Caoxu Zhang
PCPeng Cao
Peng Cao
BWBaoqing Wang
Baoqing Wang
Ferroptosis, an iron-dependent regulated cell death mechanism, holds significant promise as a therapeutic strategy in oncology. In the current study, we explored the regulatory effects of epigallocatechin gallate (EGCG), a prominent polyphenol in green tea, on ferroptosis and its potential therapeutic implications for non-small cell lung cancer (NSCLC). Treatment of NSCLC cell lines with varying concentrations of EGCG resulted in a notable suppression of cell proliferation, as evidenced by a reduction in Ki67 immunofluorescence staining. Western blot analyses demonstrated that EGCG treatment led to a decrease in the expression of glutathione peroxidase 4 (GPX4) and solute carrier family 7 member 11 (SLC7A11) while increasing the levels of acyl-CoA synthetase long-chain family member 4 (ACSL4). These molecular changes were accompanied by an increase in intracellular iron, malondialdehyde (MDA), and reactive oxygen species (ROS), alongside ultrastructural alterations characteristic of ferroptosis. Through small RNA sequencing and RT-qPCR, transfer RNA-derived small RNA 13502 (tsRNA-13502) was identified as a significant target of EGCG action, with its expression being upregulated in NSCLC tissues compared to adjacent non-tumorous tissues. EGCG was found to modulate the ferroptosis pathway by downregulating tsRNA-13502 and altering the expression of key ferroptosis regulators (GPX4/SLC7A11 and ACSL4), thereby promoting the accumulation of iron, MDA, and ROS, and ultimately inducing ferroptosis in NSCLC cells. This study elucidates EGCG’s multifaceted mechanisms of action, underscoring the modulation of ferroptosis as a viable therapeutic approach for enhancing NSCLC treatment outcomes.

1 September 2023 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
SCShi Chen
Shi Chen
YSYi Shi
Yi Shi
BHBingzhu Hu
Bingzhu Hu
JHJie Huang
Jie Huang
Purpose: To explore the association between red cell distribution width (RDW)-to-platelet ratio (RPR) and in-hospital mortality of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) patients and establish a prediction model based on RPR and other predictors. Material and Methods: This cohort study included 1922 AECOPD patients aged ≥ 18 years in the Medical Information Mart for Intensive Care (MIMIC)-III and MIMIC-IV as well as 1738 AECOPD patients from eICU Collaborative Research Database (eICU-CRD). Possible confounding factors were screened out by univariate logistic regression, and multivariable logistic regression was applied to evaluate the association between RPR and in-hospital mortality of AECOPD patients. The area under the curve (AUC), calibration curve and decision curve analysis (DCA) curve were plotted to evaluate the predictive value of the model. The median follow-up time was 3.14 (1.87, 6.25) day. Results: At the end of follow-up, there were 1660 patients survived and 262 subjects died. After adjusting for confounders, we found that Log (RPR× 1000) was linked with elevated risk of in-hospital mortality of AECOPD patients [odds ratio (OR)=1.36, 95% confidence interval (CI): 1.01– 1.84]. The prediction model was constructed using predictors including Log (RPR× 1000), age, malignant cancer, atrial fibrillation, ventilation, renal failure, diastolic blood pressure (DBP), temperature, Glasgow Coma Scale (GCS) score, white blood cell (WBC), creatinine, blood urea nitrogen (BUN), hemoglobin, infectious diseases and anion gap. The AUC of the prediction model was 0.785 (95% CI: 0.751– 0.820) in the training set, 0.721 (95% CI: 0.662– 0.780) in the testing set, and 0.795 (95% CI: 0.762– 0.827) in the validation set. Conclusion: RPR was associated with the in-hospital mortality of AECOPD patients. The prediction model for the in-hospital mortality of AECOPD patients based on RPR and other predictors presented good predictive performance, which might help the clinicians to quickly identify AECOPD patients at high risk of in-hospital mortality.